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ABSTRACT
Pharmacovigilance (PV) is an important area for the safety and ensuring that the patients are safe in every aspect of the drugs being taken or injected. 
India is still in its nascent stage; there is a lot to be done and to learn, in the field of PV, in ensuring that the safe implementation of the activities 
and work done is achieved. The major problem in India is the under-reporting of adverse drug reaction (ADR). There is an increasing number of 
hospitalization of patients owing to adverse effects of drugs and it becomes a challenge to find out the exact cause the ADRs when a patient in treated 
with multiple drugs simultaneously. In the review, we will explore the different types of assessment scale to do the ADR assessment and to find its 
causative agents.
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INTRODUCTION
Pharmacovigilance (PV), also known as drug safety, is the pharmacological 
science relating to the detection, assessment, understanding and prevention 
of adverse effects, particularly long term, and short term side effects of 
medicines [1]. PV is an important and integral part of clinical research [2]. 
The under-reporting of adverse drug reactions (ADRs) is the major setback 
worldwide which may be attributed to the lack of time and report forms. 
It has been known that the world health organization (WHO) has initiated 
the program of reporting all adverse reactions possessed by the drugs [3]. 
Moreover, its concerns have been widened to include the herbal drug 
products, traditional and complementary medicines, blood products, 
biologicals, medical devices, and vaccines. In addition, PV possesses 
various roles such as identification, quantification, and documentation 
of drug-related problems which are responsible for drug-related 
injuries [4-5]. Further, national PV programmes have been introduced 
which occupies a prime role in increasing the public awareness about drug 
safety [6-7]. This review article explains the need and importance of PV in 
daily lives of doctors and patients and the pharmaceutical industry.
 Importance of PV
It is the science which deals with the complex process of the 
understanding and explaining the nature of ADR occurred in a patient 
taking either oral or parenteral or intravenous (I.V) drugs for an 
ailment. The drugs being marketed worldwide underwent a whole 
array of tests and also underwent clinical trials in animals and human 
subjects to assess the safety of the drug for a particular disease and 
to know the exact side effects associated with it. Still there is a major 
part of it goes undetected and some of the ADR are detected in post 
marketing surveillance. It is estimated that there is significant amount 
of ADRs which decreases the quality of life, increase hospitalization 
stay and increases the mortality. A landmark study by Lazarou in 1998 
described, ADRs to be the fourth to sixth leading cause of death in the 
US and ADRs are estimated to cause 3-7% of all hospital admissions [8].
Aims of PV
PV has an important role in the assessment of side effects caused by 
the drugs whether it is caused by oral drugs; parenteral drugs or I.V. 
drugs. These drugs are pretested for ADRs before it is being marketed 
worldwide. PV has a key role in assessment, detection and identification 
of drugs which caused a particular ADRs and the mechanism by which 
it caused the injury. But to fulfill these requirements of finding and 
eliminating, a side effect is the responsibility of the doctors involved in 
the case; nurses, health workers, residents and proper guidance of the 
patients themselves help it to alleviate the root cause of ADR.
Methods used in PV
Many researchers developed different methods of causality assessment 
of ADRs by utilizing different criteria like chronological relationship 
between the administration of the drug and the occurrence of the ADR, 
screening for non-drug related causes, confirmation of the reaction by 
in vivo or in vitro tests, and antecedent information on homogeneous 
events attributed to the suspect drug or to its therapeutic class, etc., to 
define ADRs in different categories [9]. Currently, there is no universally 
accepted method for assessing causality of ADRs [10]. Currently, there 
are many algorithmic methods of causality assessment but no single 
algorithm is accepted as the gold standard because of the shortcomings 
and discordances that subsist between them [11]. We would explicate 
them in short as listed below.
Dangaumou’s French method [12]
This rule of thumb has been used by the French government agency 
since 1977. The way of doing thing separates an intrinsic imputability 
(possible case between abused substance and dispassionate event) 
from an extrinsic imputability (bibliographical data) by the agency 
of seven criteria (three connected and four semiological) in two 
different tables. The criteria are (i) drug challenge, (ii) dechallenge, 
and (iii) rechallenge by the overall score of four possible categories. 
The semiological criteria are (i) semiology (clinical signs) using per se 
(suggestive or other), (ii) favoring component, (iii) arbitrary non-drug-
related (none or possible), and (iv) laboratory tests show with three 
possible outcomes (positive, negative or no test for the event-drug 
pair). Scores are grouped as possible and dubious.
Kramer et al. method [13]
This method applies when the offending drug is administered and a 
single adverse drug event has taken place. Each adverse event is assessed 
independently and assessment is prepared. One of the advantages of 
this algorithm is its transparency. However, certain levels of experience, 
expertise, and time are required to use this method effectively.
Naranjo et al. method (Naranjo scale) [14]
It is utilized to verify causality in a variety of clinical situations utilizing the 
categories and definitions of definite, probable, possible, and doubtful. It 
consists of ten questions which are answered as yes, no and unknown. The 
event is assigned to a probability category predicated on the total score after 
totaling. A total score of ≥9 is definite, probable is 5-8, possible is 1-4 and 
doubtful ≥0. This scale is more powerful when the adverse event is associated 
with only one drug, but when multiple drugs are involved or there is any 
interactions between drugs, this scale fails to identify the offending agent.
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Balanced assessment method [15]
This method evaluates a case report on various visual analog scale 
(VAS) models that each criterion is fulfilled individually. It has an 
added advantage that it considers an alternative causative factor as 
a possibility and not just as a separate factor. Each case is assessed 
independently by different assessors and the evaluation depends on 
the assessor’s skills knowledge.
Ciba-Geigy method [16]
Expert consensus meetings have resulted in Ciba-Geigy method. 
Experts used their clinical judgment to assess adverse drug events 
and assign causality on a VAS. This method uses a checklist which is 
composed of 23 questions, which is split into three sections: (i) History 
of present adverse reaction, (ii) patient’s past adverse-reaction history, 
and (iii) monitoring-physician’s experience. This updated method was 
found to have a high degree of agreement (62%) when compared with 
evaluator’s assessments.
Loupi et al. method [17]
This method developed to assess the teratogenic potential of drug. The 
first sections of the algorithm sanction for the drug to be omitted if 
not implicated in the inception of the abnormality. The second section 
weighs the bibliographical data. The three questions consider alternative 
etiological candidates other than the drug; chronology of the suspect 
drug and other bibliographical data, to arrive at a conclusion on causality.
Roussel Uclaf causality assessment method [9]
This method is used in disease states such as liver and dermatological 
problems. A retrospect assessment of the reproducibility of this method 
among four experts had showed a 37-99% agreement rate.
Australian method [18]
Australian method involves the evidence which helps in to draw the 
conclusion, such as timing, and laboratory information from case 
reports presented and the antecedent cognizance on the suspect drug 
profile is deliberately omitted in the assessment.
Probabilistic or Bayesian approaches
It utilizes concrete findings in a case to transform a prior into a posterior 
probability of drug causation [19]. The prior probability is calculated 
from epidemiological information and the posterior probability 
cumulates this background information with the evidence in the 
individual case. It is open-ended approach with no circumscription to 
the amount of case details that can be assessed utilizing this method. 
Simultaneous assessment of multiple causes can be assessed [20].
WHO-Uppsala monitoring centre (UMC) causality assessment 
criteria [21]
The WHO-UMC causality assessment method includes the following criteria
• Certain-adverse event and the time relationship associated with it
• Probable/likely-unlikely to attribute the other drugs or diseases
• Possible-this can be explained by the drug intake or another disease
• Unlikely-adverse event can be explained with the time relationship 
associated with it but its not impossible
• Conditional/unclassi ied-more data in needed to make a proper assessment
• Unassessable/unclassi iable-an adverse event is suggested but more 
data are needed to make an assessment.
CONCLUSION
PV remains a dynamic part of the clinicians and the general population. 
After the appearance of these adverse drugs effects, it is very essential 
that these are reported timely and analyzed. Not only the doctors 
should be aware of the PV programme but the patients themselves 
should be made aware of this so self-reporting is increased and the 
burden on the clinicians is also reduced. India is still in the growing 
phase of PV and more reporting is necessary to reach the world’s 
standard of reporting these adverse events to provide effective drug 
use in children’s and pregnant women which is one of the most 
vulnerable populations of all. The PV programme must be able to 
identify these adverse events timely in the coming years with the help 
of clinicians, patients, and the pharmaceutical industry to help shape 
the safety of patients themselves.
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